期刊
SEMINARS IN DIAGNOSTIC PATHOLOGY
卷 30, 期 3, 页码 158-164出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.semdp.2013.06.002
关键词
Pituitary adenoma; Classification; Pegvisomant; Temozolomide; Dopamine agonists; Somatostatin
Recent data suggest that 1 of 5 individuals in the general population is affected with a pituitary adenoma. Many of these neoplasms are clinically non-functioning adenomas that may be small and clinically undetected or may present as mass lesions; others are hormonally active and cause significant morbidity due to the metabolic effects of hormone excess (e.g., acromegaly and cushing's disease). In either case, they can grow and invade adjacent anatomic structures. Tumors with similar clinical features are morphologically heterogenous and detailed comprehensive classification of pituitary adenomas is important to predict specific clinical behaviors and genetic changes that serve as targets for therapy. We provide a practical approach to clinical diagnosis and highlight the pitfalls in the classification of these common neoplasms. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据